Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

$KAST News – Kasten Inc. Completes Merger With Dakota Life Sciences

Tuesday, March 7, 2017 6:45
% of readers think this story is Fact. Add your two cents.

(Before It's News)

FinancialNewsMedia.com News Alert: SILVER SPRINGS, Nevada, – (http://www.financialnewsmedia.com News Alert) – Kasten, Inc. (OTC: KAST) announced today that it has completed a merger with Thru Pharma LLC dba DAKOTA Life Sciences. Upon review of Dakota during the phases of the JV setup, the Board of Directors and Members of Kasten and Dakota determined, it was in the best interests of both entities and their stockholders to consummate the merger of Kasten with and into Dakota with Kasten as the surviving entity.

Dakota Life Sciences is engaged in developing innovative health products utilizing Site Specific Penetration Technology SSPT(TM) technologies. These products include but are not limited to Thin Nail(R) (OTC First Aid Nail Antifungal), Symphony(TM) OTC First Aid Antibiotic, ThinNail(R) RX Topical Antifungal, Symphony(TM) RX Topical Antibiotic, Reserve(TM) Rx Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology products, as well as other valuable life sciences technologies. Read this and more news for Kasten at: http://financialnewsmedia.com/profiles/kast.html

Dakota Life Sciences is a leading anti-infectives private pharmaceutical company with award-winning products designed to provide the highest efficacy for global patients at high risk of suffering from dangerous microbial and fungal infections.

“Dakota Life Sciences is the solution to take Kasten to the next level. They have a driven experienced management team and the product line already in place to enhance shareholder value,” stated Jose Delgado, CEO of Kasten, Inc.

“Dakota Life Sciences is very pleased to combine forces with Kasten,” said the President of Dakota Life Sciences, Steven Keough. “Our joint focus is to introduce a range of high efficacy affordable prescription and OTC pharmaceutical products that are unique to the market.”

CONTACT:

Kasten, Inc.

702-860-2407

[email protected]

SOURCE Kasten, Inc.

Disclaimer:

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended…



Source: http://www.financialnewsmedia.com/stock-investing-business-investing-news/featured-news.php?id=985

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.